PAREXEL Launches Perceptive® Cloud for the Life Sciences Industry
BOSTON, December 12, 2017-PAREXEL International Corporation, a leading global biopharmaceutical services organization, today introduced the Perceptive® Cloud to the life sciences industry, as part of the organization’s recent alliance with Microsoft Corp.
Perceptive Cloud elevates PAREXEL Informatics solutions into an enhanced cloud infrastructure built on Microsoft Azure, combining PAREXEL’s extensive industry expertise and innovative technology solutions with the power of Microsoft’s intelligent cloud services and investment in global compliance certifications and enterprise-grade security. The first group of integrated cloud services will include LIQUENT InSight® Regulatory Information Management (RIM), Study Start-Up, DataLabs® Electronic Data Capture (EDC), Managed Access Programs, and IMPACT ® Clinical Trial Management (CTMS).
“In drug development today, the time to treatment continues to grow longer. This is due, in large part, to the use of conventional, disparate systems that simply digitize manual processes,” said Paul Bidez, Vice President of Regulatory and Clinical Solutions for PAREXEL. “Perceptive Cloud represents an opportunity to automate and streamline workflows and provide greater access to high quality data, simplifying the drug development journey with the objective of ultimately bringing new therapies to patients sooner.”
Perceptive Cloud is designed to respond to the need within healthcare to deliver cost-effective innovation while trusting that sensitive information will stay secure across global environments. Introducing Perceptive Cloud represents the first milestone of the enterprise alliance between PAREXEL and Microsoft aimed at leveraging the cloud to optimize performance and jointly innovate to offer new clinical development solutions and more site- and patient-centric technologies.
“Most life sciences solutions to date have been developed with the end result in mind, not the user experience, creating bottlenecks and inefficiencies across the drug development chain,” said Paul Slater, Worldwide Industry Strategist, Pharmaceuticals, Microsoft Health. “Both Microsoft and PAREXEL are committed to developing technologies that better engage patients, sites and sponsors to optimize clinical and operational effectiveness and digitally transform health. The Perceptive Cloud is only the first step in this effort.”
PAREXEL Informatics delivers innovative technology solutions to help optimize patient engagement, clinical and regulatory processes, and provides analytics and visualization for PAREXEL’s Connected Journey™ of data-driven services. PAREXEL’s Connected Journey of technology, processes, and expertise supports clinical development and commercialization, with solutions to provide data-driven insights that enable our clients to make critical decisions more quickly. For more information on Perceptive Cloud, visit www.PAREXEL.com/Perceptive-Cloud.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions intended to expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has approximately 18,900 employees with offices in 85 locations in 52 countries around the world. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
# # #
PAREXEL Contacts:
Media:
Wendy Ryan
Tel.: +1 781-434-5104
Email: Wendy.Ryan@PAREXEL.com
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie@PAREXEL.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
